vs

Side-by-side financial comparison of HAEMONETICS CORP (HAE) and INNOSPEC INC. (IOSP). Click either name above to swap in a different company.

HAEMONETICS CORP is the larger business by last-quarter revenue ($1.3B vs $453.2M, roughly 2.9× INNOSPEC INC.). HAEMONETICS CORP runs the higher net margin — 7.3% vs 6.8%, a 0.5% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (4.8% vs 2.8%). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (99.2% CAGR vs 2.1%).

Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.

Innospec Inc., formerly known as Octel Corporation and Associated Octel Company, Ltd., is an American specialty chemical company. It comprises three business units:The Performance Chemicals business trades in the personal care, home care, agrochemical, mining and industrial markets. The Fuel Specialties business specializes in manufacturing and supplying fuel additives. The Oilfield Services business supplies drilling, completion and production chemicals.

HAE vs IOSP — Head-to-Head

Bigger by revenue
HAE
HAE
2.9× larger
HAE
$1.3B
$453.2M
IOSP
Growing faster (revenue YoY)
HAE
HAE
+2.0% gap
HAE
4.8%
2.8%
IOSP
Higher net margin
HAE
HAE
0.5% more per $
HAE
7.3%
6.8%
IOSP
Faster 2-yr revenue CAGR
HAE
HAE
Annualised
HAE
99.2%
2.1%
IOSP

Income Statement — Q4 FY2026 vs Q1 FY2026

Metric
HAE
HAE
IOSP
IOSP
Revenue
$1.3B
$453.2M
Net Profit
$97.3M
$30.8M
Gross Margin
14.9%
27.3%
Operating Margin
83.4%
8.1%
Net Margin
7.3%
6.8%
Revenue YoY
4.8%
2.8%
Net Profit YoY
-42.0%
-8.3%
EPS (diluted)
$1.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HAE
HAE
IOSP
IOSP
Q1 26
$1.3B
$453.2M
Q4 25
$339.0M
$455.6M
Q3 25
$327.3M
$441.9M
Q2 25
$321.4M
$439.7M
Q1 25
$330.6M
$440.8M
Q4 24
$348.5M
$466.8M
Q3 24
$345.5M
$443.4M
Q2 24
$336.2M
$435.0M
Net Profit
HAE
HAE
IOSP
IOSP
Q1 26
$97.3M
$30.8M
Q4 25
$44.7M
$47.4M
Q3 25
$38.7M
$12.9M
Q2 25
$34.0M
$23.5M
Q1 25
$58.0M
$32.8M
Q4 24
$37.5M
$-70.4M
Q3 24
$33.8M
$33.4M
Q2 24
$38.4M
$31.2M
Gross Margin
HAE
HAE
IOSP
IOSP
Q1 26
14.9%
27.3%
Q4 25
59.7%
28.0%
Q3 25
59.5%
26.4%
Q2 25
59.8%
28.0%
Q1 25
58.4%
28.4%
Q4 24
55.5%
29.2%
Q3 24
54.2%
28.0%
Q2 24
52.0%
29.2%
Operating Margin
HAE
HAE
IOSP
IOSP
Q1 26
83.4%
8.1%
Q4 25
19.9%
10.3%
Q3 25
17.9%
1.3%
Q2 25
16.8%
7.8%
Q1 25
21.6%
9.6%
Q4 24
16.9%
8.8%
Q3 24
15.0%
10.3%
Q2 24
11.8%
9.4%
Net Margin
HAE
HAE
IOSP
IOSP
Q1 26
7.3%
6.8%
Q4 25
13.2%
10.4%
Q3 25
11.8%
2.9%
Q2 25
10.6%
5.3%
Q1 25
17.5%
7.4%
Q4 24
10.8%
-15.1%
Q3 24
9.8%
7.5%
Q2 24
11.4%
7.2%
EPS (diluted)
HAE
HAE
IOSP
IOSP
Q1 26
$1.22
Q4 25
$0.95
$1.90
Q3 25
$0.81
$0.52
Q2 25
$0.70
$0.94
Q1 25
$1.17
$1.31
Q4 24
$0.74
$-2.80
Q3 24
$0.66
$1.33
Q2 24
$0.74
$1.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HAE
HAE
IOSP
IOSP
Cash + ST InvestmentsLiquidity on hand
$245.4M
$289.1M
Total DebtLower is stronger
$1.2B
Stockholders' EquityBook value
$796.3M
$1.4B
Total Assets
$2.4B
$1.8B
Debt / EquityLower = less leverage
1.53×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HAE
HAE
IOSP
IOSP
Q1 26
$245.4M
$289.1M
Q4 25
$363.4M
$292.5M
Q3 25
$296.4M
$270.8M
Q2 25
$292.9M
$266.6M
Q1 25
$306.8M
$299.8M
Q4 24
$320.8M
$289.2M
Q3 24
$299.3M
$303.8M
Q2 24
$344.4M
$240.2M
Total Debt
HAE
HAE
IOSP
IOSP
Q1 26
$1.2B
Q4 25
$1.2B
Q3 25
$1.2B
Q2 25
$1.2B
Q1 25
$1.2B
Q4 24
Q3 24
Q2 24
Stockholders' Equity
HAE
HAE
IOSP
IOSP
Q1 26
$796.3M
$1.4B
Q4 25
$911.5M
$1.3B
Q3 25
$849.2M
$1.3B
Q2 25
$882.3M
$1.3B
Q1 25
$820.8M
$1.3B
Q4 24
$906.9M
$1.2B
Q3 24
$878.9M
$1.2B
Q2 24
$905.4M
$1.2B
Total Assets
HAE
HAE
IOSP
IOSP
Q1 26
$2.4B
$1.8B
Q4 25
$2.5B
$1.8B
Q3 25
$2.4B
$1.8B
Q2 25
$2.5B
$1.8B
Q1 25
$2.5B
$1.8B
Q4 24
$2.5B
$1.7B
Q3 24
$2.5B
$1.8B
Q2 24
$2.5B
$1.7B
Debt / Equity
HAE
HAE
IOSP
IOSP
Q1 26
1.53×
Q4 25
1.34×
Q3 25
1.44×
Q2 25
1.39×
Q1 25
1.49×
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HAE
HAE
IOSP
IOSP
Operating Cash FlowLast quarter
$293.2M
$17.6M
Free Cash FlowOCF − Capex
$209.9M
FCF MarginFCF / Revenue
15.7%
Capex IntensityCapex / Revenue
2.5%
2.0%
Cash ConversionOCF / Net Profit
3.01×
0.57×
TTM Free Cash FlowTrailing 4 quarters
$417.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HAE
HAE
IOSP
IOSP
Q1 26
$293.2M
$17.6M
Q4 25
$93.6M
$61.4M
Q3 25
$111.3M
$39.3M
Q2 25
$17.4M
$9.3M
Q1 25
$116.6M
$28.3M
Q4 24
$43.8M
$25.7M
Q3 24
$48.8M
$73.5M
Q2 24
$-27.4M
$4.7M
Free Cash Flow
HAE
HAE
IOSP
IOSP
Q1 26
$209.9M
Q4 25
$87.2M
$46.8M
Q3 25
$106.3M
$25.0M
Q2 25
$13.6M
$-3.7M
Q1 25
$100.9M
$19.9M
Q4 24
$35.2M
$13.6M
Q3 24
$39.4M
$65.8M
Q2 24
$-33.1M
$-6.2M
FCF Margin
HAE
HAE
IOSP
IOSP
Q1 26
15.7%
Q4 25
25.7%
10.3%
Q3 25
32.5%
5.7%
Q2 25
4.2%
-0.8%
Q1 25
30.5%
4.5%
Q4 24
10.1%
2.9%
Q3 24
11.4%
14.8%
Q2 24
-9.8%
-1.4%
Capex Intensity
HAE
HAE
IOSP
IOSP
Q1 26
2.5%
2.0%
Q4 25
1.9%
3.2%
Q3 25
1.5%
3.2%
Q2 25
1.2%
3.0%
Q1 25
4.7%
1.9%
Q4 24
2.5%
2.6%
Q3 24
2.7%
1.7%
Q2 24
1.7%
2.5%
Cash Conversion
HAE
HAE
IOSP
IOSP
Q1 26
3.01×
0.57×
Q4 25
2.09×
1.30×
Q3 25
2.88×
3.05×
Q2 25
0.51×
0.40×
Q1 25
2.01×
0.86×
Q4 24
1.17×
Q3 24
1.44×
2.20×
Q2 24
-0.71×
0.15×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons